Resistance Exercise and Inflammation in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy: Mediation Analysis From a Randomized, Controlled Intervention Trial

Schmidt, Martina E.; Meynköhn, Anna; Habermann, Nina; Wiskemann, Joachim; Oelmann, Jan; Hof, Holger; Wessels, Sabine; Klassen, Oliver; Debus, Jürgen; Potthoff, Karin; Steindorf, Karen; Ulrich, Cornelia M.

doi:10.1016/j.ijrobp.2015.10.058

Cited by 72 publications

(91 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For instance, in a RCT examining the effect of physical exercise on fatigue and on the levels of inflammatory markers in patients with breast cancer following radiation therapy, a program of progressive resistance exercise was effective in counteracting the increase in IL-6 levels and IL 6/IL-1RA ratio associated with radiation therapy 192 . The impact of physical exercise on fatigue was partially attributable to the reduction in the levels of inflammatory markers.…”

Section: Physical Activitymentioning

confidence: 99%

Depression in cancer: The many biobehavioral pathways driving tumor progression

Bortolato

Hyphantis

Valpione

et al. 2017

Cancer Treatment Reviews

248

179

View full text Add to dashboard Cite

Major Depressive Disorder (MDD) is common among cancer patients, with prevalence rates up to four-times higher than the general population. Depression confers worse outcomes, including non-adherence to treatment and increased mortality in the oncology setting. Advances in the understanding of neurobiological underpinnings of depression have revealed shared biobehavioral mechanisms may contribute to cancer progression. Moreover, psychosocial stressors in cancer promote:(1) inflammation and oxidative/nitrosative stress; (2) a decreased immunosurveillance; and (3) a dysfunctional activation of the autonomic nervous system and of the hypothalamic-pituitary-adrenal axis. Consequently, the prompt recognition of depression among patients with cancer who may benefit of treatment strategies targeting depressive symptoms, cognitive dysfunction, fatigue and sleep disturbances, is a public health priority. Moreover, behavioral strategies aiming at reducing psychological distress and depressive symptoms, including addressing unhealthy diet and life-style choices, as well as physical inactivity and sleep dysfunction, may represent important strategies not only to treat depression, but also to improve wider cancer-related outcomes. Herein, we provide a comprehensive review of the intertwined biobehavioural pathways linking depression to cancer progression. In addition, the clinical implications of these findings are critically reviewed.

show abstract

Section: Physical Activitymentioning

confidence: 99%

Depression in cancer: The many biobehavioral pathways driving tumor progression

Bortolato

Hyphantis

Valpione

et al. 2017

Cancer Treatment Reviews

248

179

View full text Add to dashboard Cite

show abstract

“…In humans, resistance exercise has been shown to prevent increases in IL‐6 during treatment for breast cancer . Further, low‐intensity, low‐volume resistance exercise in rodents reduced inflammatory cytokines .…”

Section: Muscle Loss In Cancer Patientsmentioning

confidence: 99%

“…Further, the utility of exercise as a nonpharmacological intervention for muscle mass and muscle function appears to be most beneficial in patients with metastatic cancer who are precachectic. Exercise has been shown to decrease circulating levels of IL‐6 in patients with a cancer diagnosis . Additionally, resistance training upregulates IGF‐1, which results in activation of the downstream pathway IRS1/PI3K/Akt, and aerobic exercise has been shown to increase production of PGC‐1α4 .…”

Section: Potential Pharmacological and Nonpharmacological Therapeuticsmentioning

confidence: 99%

Cancer‐ and Chemotherapy‐Induced Musculoskeletal Degradation

et al. 2019

View full text Add to dashboard Cite

Mobility in advanced cancer patients is a major health care concern and is often lost in advanced metastatic cancers. Erosion of mobility is a major component in determining quality of life but also starts a process of loss of muscle and bone mass that further devastates patients. In addition, treatment options become limited in these advanced cancer patients. Loss of bone and muscle occurs concomitantly. Advanced cancers that are metastatic to bone often lead to bone loss (osteolytic lesions) but may also lead to abnormal deposition of new bone (osteoblastic lesions). However, in both cases there is a disruption to normal bone remodeling and radiologic evidence of bone loss. Many antitumor therapies can also lead to loss of bone in cancer survivors. Bone loss releases cytokines (TGFβ) stored in the mineralized matrix that can act on skeletal muscle and lead to weakness. Likewise, loss of skeletal muscle mass leads to reduced bone mass and quality via mechanical and endocrine signals. Collectively these interactions are termed bone‐muscle cross‐talk, which has garnered much attention recently as a prime target for musculoskeletal health. Pharmacological approaches as well as nutrition and exercise can improve muscle and bone but have fallen short in the context of advanced cancers and cachexia. This review highlights our current knowledge of these interventions and discusses the difficulties in treating severe musculoskeletal deficits with the emphasis on improving not only bone mass and muscle size but also functional outcomes. © 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.

show abstract

“…At baseline, IL-1Ra did not correlate with higher fatigue levels and had no influence on changes of fatigue severity during treatment. The most recent study, performed by Schmidt et al, did find a small but significant influence of increased IL-6/IL-1Ra ratio after treatment, which could not be found for IL-1Ra levels ( r = 0.25) [96]. …”

Section: Overview Of Studies Investigating the Role Of Interleukin-1 mentioning

confidence: 99%

Interleukin-1 as a mediator of fatigue in disease: a narrative review

Roerink

Schaaf

Dinarello

et al. 2017

J Neuroinflammation

View full text Add to dashboard Cite

Fatigue is commonly reported in a variety of illnesses, and it has major impact on quality of life. Previously, it was thought that fatigue originates in the skeletal muscles, leading to cessation of activity. However, more recently, it has become clear that the brain is the central regulator of fatigue perception. It has been suggested that pro-inflammatory cytokines, especially interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β), play a prominent role in the development of central fatigue, and several studies have been performed to elucidate the connection between inflammation and these central processes.In this narrative review, mechanisms of action of IL-1 are described, with special attention to its effect on the central nervous system. In addition, we present a summary of studies that (i) investigated the relationship between circulating IL-1α and IL-1β and fatigue severity and/or (ii) evaluated the effect of inhibiting IL-1 on fatigue. We aim to improve the understanding of fatigue in both inflammatory and non-inflammatory illnesses, which could help develop strategies to treat fatigue more effectively.Reviewing the studies that have been performed, it appears that there is a limited value of measuring circulating IL-1. However, inhibiting IL-1 has a positive effect on severe fatigue in most studies that have been conducted.

show abstract

Resistance Exercise and Inflammation in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy: Mediation Analysis From a Randomized, Controlled Intervention Trial

Cited by 72 publications

References 39 publications

Depression in cancer: The many biobehavioral pathways driving tumor progression

Depression in cancer: The many biobehavioral pathways driving tumor progression

Cancer‐ and Chemotherapy‐Induced Musculoskeletal Degradation

Interleukin-1 as a mediator of fatigue in disease: a narrative review

Contact Info

Product

Resources

About